Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-R-CHP in HIV-Related Diffuse Large B-Cell Lymphoma (China, Real-World)
ChiCTR2600125350Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polatuzumab vedotin in AIDS-associated diffuse large B-cell lymphoma (AIDS-DLBCL), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Investigator-assessed Complete Response Rate (CRR). Planned start May 2026; status: not yet recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
AIDS-associated diffuse large B-cell lymphoma (AIDS-DLBCL)
Beyond the preview
Go deeper on ChiCTR2600125350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125350.